These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 1094102

  • 21. [Prodectin treatment of partial hearing loss as a result of atherosclerosis].
    Smirnova NA, Timakov VA, Mikushkin MK.
    Vestn Otorinolaringol; 1982; (6):53-6. PubMed ID: 7179649
    [No Abstract] [Full Text] [Related]

  • 22. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
    Hunyi L.
    Ther Hung; 1976; 24(2):67-71. PubMed ID: 982342
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Comparison of conservative (Prodectin) treatment and surgical intervention in arteriosclerotic obliterative diseases of the lower extremities.
    Hunyi L.
    Ther Hung; 1978; 26(2):77-80. PubMed ID: 684660
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Study of pyridinolcarbamate in the treatment of diabetic angiopathies and atheromatous arteritis].
    Plauchu M, Bussy L, Rondelet J.
    Lyon Med; 1972 Feb 13; 227(3):271-7. PubMed ID: 5037162
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Comparative double-blind study on the normolipemic effect of clofibrate and a clofibrate-mucopolysaccharide extract combination].
    Cagli V, Lillo V.
    Clin Ter; 1975 Oct 31; 75(2):153-69. PubMed ID: 132333
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [The clofibrate-dipyridamole combination in the prevention and therapy of arteriosclerotic vascular disease and its complications].
    Cucinotta D, Ferretti PG, Daccò L, Mazzera F.
    G Clin Med; 1977 Oct 31; 58(11-12):475-86. PubMed ID: 608558
    [No Abstract] [Full Text] [Related]

  • 34. [Therapeutic effect of pyridylcarbinolic ester of clofibric acid on the changes of the lipid and fibrinolytic picture in arteriosclerotic patients].
    Rugginenti.
    Minerva Med; 1974 May 09; 65(35):1906-16. PubMed ID: 4601840
    [No Abstract] [Full Text] [Related]

  • 35. The effect of Prodectin (pyridinolcarbamate) treatment of the circulation rate in obliterating arterial diseases of the lower extremities.
    Fényes G, Gótzy G, Fehrentheil L.
    Ther Hung; 1975 May 09; 23(2):64-66. PubMed ID: 1188705
    [No Abstract] [Full Text] [Related]

  • 36. [Mechanism of action and clinical effectiveness of the new Soviet-made drug parmidin in the treatment of arteriosclerosis and ischemic heart disease].
    Kukes VG, Mashkovskiĭ MD, Paskhina TS, Borisov VG, Shvarts GIa.
    Kardiologiia; 1978 Oct 09; 18(10):61-8. PubMed ID: 213636
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Clinical evaluation of the therapeutic activity of the beta-pyridyl-carbinolic ester of clofibric acid].
    Silingardi V, Renzi R, Mora A, Di Prisco AU.
    Minerva Med; 1973 Mar 21; 64(16):751-69. PubMed ID: 4579325
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.